Evidence map›Paper›PMID 25984742›Full record

ReviewNutrients2015

Redox-active selenium compounds--from toxicity and cell death to cancer treatment.

Sougat Misra, Mallory Boylan, Arun Selvam, Julian E Spallholz, Mikael Björnstedt

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 1 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 1 synthesis or guideline pooled it, 307 citations in OpenAlex.

  1. Selenium for preventing cancer.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Preparation and In Vitro Bioactivity Evaluation ofFoods (Basel, Switzerland) · 2026
    Article
  20. Review

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Sougat MisraDivision of Pathology F46, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm 141 86, Sweden. sougat.misra@ki.se.
Mallory BoylanDepartment of Nutritional Sciences, College of Human Sciences, Texas Tech University, P.O. Box 41270, Lubbock, TX 79409-1270, USA. mallory.boylan@ttu.edu.
Arun SelvamDivision of Pathology F46, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm 141 86, Sweden. arun.selvam@ki.se.
Julian E SpallholzDepartment of Nutritional Sciences, College of Human Sciences, Texas Tech University, P.O. Box 41270, Lubbock, TX 79409-1270, USA. Julian.Spallholz@ttu.edu.
Mikael BjörnstedtDivision of Pathology F46, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm 141 86, Sweden. Mikael.Bjornstedt@ki.se.
Karolinska University Hospital · SETexas Tech University · USKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selenium is generally known as an antioxidant due to its presence in selenoproteins as selenocysteine, but it is also toxic. The toxic effects of selenium are, however, strictly concentration and chemical species dependent. One class of selenium compounds is a potent inhibitor of cell growth with remarkable tumor specificity. These redox active compounds are pro-oxidative and highly cytotoxic to tumor cells and are promising candidates to be used in chemotherapy against cancer. Herein we elaborate upon the major forms of dietary selenium compounds, their metabolic pathways, and their antioxidant and pro-oxidant potentials with emphasis on cytotoxic mechanisms. Relative cytotoxicity of inorganic selenite and organic selenocystine compounds to different cancer cells are presented as evidence to our perspective. Furthermore, new novel classes of selenium compounds specifically designed to target tumor cells are presented and the potential of selenium in modern oncology is extensively discussed.

Indexed as

Drug DesignAnimalsAntineoplastic AgentsAntioxidantsHumansNeoplasmsOrganoselenium CompoundsOxidation-ReductionSelenium CompoundsSelenoproteinsAntineoplastic AgentsAntioxidantsOrganoselenium CompoundsSelenium CompoundsSelenoproteinsantioxidantscancercytotoxicityseleniumselenoproteinstumor

Identifiers

PMID25984742
PMCPMC4446766
OpenAlexW2161500896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.